Vanda Pharmaceuticals | VNDA - Capitaux D'Emprunt





Capitaux D'Emprunt Changement Date
Acadia Pharmaceuticals USD 0 0 2025-03
Agios Pharmaceuticals USD 1.06M 0 2022-09
Akebia Therapeutics USD 36.39M 11.85M 2026-03
Alnylam Pharmaceuticals USD 2.48B 931K 2026-03
Arrowhead Research USD 1.23B 687.3M 2026-03
AstraZeneca USD 25.96B 177M 2026-03
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Eli Lilly USD 39.37B 1.5B 2026-03
Enanta Pharmaceuticals USD 0 0 2024-12
Esperion Therapeutics USD 457.65M 9.5M 2025-12
Halozyme Therapeutics USD 1.94B 206.73M 2026-03
Heron Therapeutics USD 140.64M 975K 2025-12
Insmed USD 542.22M 1.25M 2026-03
J&J USD 37.53B 1.91B 2026-03
Lexicon Pharmaceuticals USD 49.68M 276K 2026-03
Ligand Pharmaceuticals USD 446.19M 702K 2025-12
Merck USD 46.67B 77M 2026-03
Minerva Neurosciences USD 0 86.58M 2024-09
Moderna USD 603M 7M 2026-03
Novartis USD 29.59B 5.35B 2025-12
Pfizer USD 60.57B 1.08B 2026-03
PTC Therapeutics USD 286.94M 1.74B 2026-03
Puma Biotechnology USD 10.87M 222K 2025-06
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 13.84B 1.88B 2026-03
Takeda JPY 4.37T 99.51B 2026-03
Teva Pharmaceutical Industries USD 14.02B 971M 2026-03
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Vanda Pharmaceuticals USD 3.15M 3.15M 2024-12
Veracyte USD 0 0 2025-03